Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Ross Moat Sells 1,703 Shares

Key Points

• COO Ross Moat executed pre-arranged Rule 10b5-1 sales of 1,703 shares on April 9 and 2,367 shares on April 6 — totaling 4,070 shares for about $194,502 and leaving him with 12,029 shares.
• Kiniksa shares traded near $47.30 (up 0.5%); the company reported Q4 EPS of $0.17 (missing estimates) with revenue up 65% YoY to $202.13M, and analysts hold a "Moderate Buy" consensus with an average price target of $55.29.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Ross Moat sold 1,703 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $79,513.07. Following the completion of the transaction, the chief operating officer owned 12,029 shares in the company, valued at $561,634.01. The trade was a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Monday, April 6th, Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $48.58, for a total value of $114,988.86.

Kiniksa Pharmaceuticals International Stock Up 0.5%

Kiniksa Pharmaceuticals International stock traded up $0.22 during mid-day trading on Monday, reaching $47.30. 349,649 shares of the company's stock were exchanged, compared to its average volume of 641,653. The business's fifty day simple moving average is $45.95 and its 200 day simple moving average is $42.36. Kiniksa Pharmaceuticals International, plc has a one year low of $19.41 and a one year high of $50.03. The firm has a market capitalization of $3.62 billion, a PE ratio of 63.92 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same quarter last year, the company earned ($0.12) EPS. The firm's revenue for the quarter was up 65.0% compared to the same quarter last year. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mark Sheptoff Financial Planning LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company's stock worth $674,000 after purchasing an additional 250 shares in the last quarter. Mariner LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company's stock valued at $558,000 after buying an additional 266 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company's stock worth $678,000 after buying an additional 406 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company's stock worth $317,000 after buying an additional 508 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on KNSA. Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a "buy" rating and a $62.00 target price for the company. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $55.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.